Medical Doctor | Phase I Medical Oncologist and Neuro-oncologist in @HumanitasMilano 💊🧠 | Across @ErasmusMC 🔬and @UniCatt 📚 | @EANO YC 🧠 🇪🇺
Milano, Lombardia
Joined September 2015
- Tweets4.6K
- Following2.5K
- Followers1.6K
- Likes9.3K
Pinned Tweet
Just out in @ESMO_Open our large experience exploring prognostic signature of patients with astrocytoma IDHm G4‼️🤩
Shedding some light on this “grey-zone” entity between IDHm and IDHwt gliomas! 🔦🧠
@EANOassociation
sciencedirect.com/science/ar…
Angelo Dipasquale retweeted
🧬 Liquid biopsy may be transforming precision oncology—but are healthcare systems keeping up?
Article 📰
sciencedirect.com/science/ar…
Liquid biopsy in oncology practice: A global survey by the Young Committee of the International Society of Liquid Biopsy (ISLB) done in collaboration with OncoAlert 🚨
A global survey of 393 oncology providers across 59 countries 🌐 reveals that liquid biopsy 🩸 is widely valued but inconsistently implemented.
➡️ While 88% consider it important, use remains limited, with major differences by region, income level, and practice setting. Cost, test availability, interpretation challenges, and turnaround time were key barriers.
✅ Structured workflows and molecular tumor board support also varied substantially, highlighting the need for context-specific strategies to expand equitable implementation.
@eleonora_nicolo
@SurbhiSinghalMD
@ESaldanhaMD
@KonVenetis
@letipontolillo
@ddemiguelperez
@AngeloDipa_
@nnadiagee
@PasqualePisapia
@A_OrtegaFranco
@mgoudaMD
@DrMirallas
@ErulEnes
@weoncologists
@RobertoBoreaMD
@ReduzziCarol
@isliquidbiopsy
Pinging
@ChristianRolfo
@UmbertoMalapel1
@matteolambe
@DrYukselUrun
@tompowles1
@PGrivasMDPhD
@scocmem
@nataliagandur
@to_be_elizabeth
@CathyEngMD
@BenWestphalen
@graokane
@christine_lovly
@BRicciutiMD
@UOzkerim
@DrVilmaPBarcia
@DraMartinezLago
Angelo Dipasquale retweeted
doi.org/10.1200/JCO-25-01846
Kudos @RadOncConnor @TonyWangMD @gminniti2012 @AngeloDipa_ @fabiomoraesmd & colleagues
1000+ patients
Age is predictive for IDHwt
Angelo Dipasquale retweeted
#ASCO26
“Atypical” EGFR mutations are no longer an afterthought in NSCLC.
We’re finally seeing dedicated prospective data instead of small retrospective series.
Key signals:
🟢 Afatinib: early benchmark activity
🟢 Osimertinib: CNS-friendly option
🟢 Furmonertinib: ORR up to 68%
🟢 Amivantamab + lazertinib: promising durability with mPFS nearing 20 months in 1L
Most exciting update:
🧬 ALPACCA is now the first randomized phase III trial dedicated to PACC atypical EGFR mutations.
After years of lumping these patients together, precision treatment for uncommon EGFR is finally becoming real.
#OncoTwitter #MedTwitter #LungCancer @OncoAlert @myesmo @esmo_open @ASCO @larvol
Angelo Dipasquale retweeted
#ASCO26 is coming! 🩸
Check the selected #liquidbiopsy oral presentations for this year by the @isliquidbiopsy Young Committee!
Save the dates 📅 and look forward to our upcoming editorial! 📰
@OSUCCC_James @ChristianRolfo @UmbertoMalapel1 @drgandara
Angelo Dipasquale retweeted
New online! Time as an unmeasured ‘dose’ in oncology: introducing time budgeting as a design principle for cancer care dlvr.it/TS8L67
Angelo Dipasquale retweeted
Review @NatureCancer @BizarMd @elhamazizi @Columbia
Single-cell and spatial profiling in cancer biology and clinical oncology
nature.com/articles/s43018-0…
Angelo Dipasquale retweeted
Evolution of bispecific and multispecific antibodies in cancer therapy - The Lancet Regional Health – Europe thelancet.com/journals/lanep…
Angelo Dipasquale retweeted
KRAS inhibitors have been used to treat pancreatic cancer, but can they PREVENT cancer from occurring altogether? In @ScienceMagazine from @PennCancer
Cancer interception with KRAS inhibitors in preclinical models of #PancreaticCancer
science.org/doi/10.1126/scie…
Angelo Dipasquale retweeted
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
Great review👇
nature.com/articles/s41571-0…
Out on @JNeurooncol our proof-of-concept experience exploring IDH mutation blockade after surgery in patients with WHO Grade 3 IDH+ gliomas!
link.springer.com/article/10…
TIGIT as example of the Network Effect we are living in drug discovery nature.com/articles/d41573-0…
Angelo Dipasquale retweeted
Check out this real world (England) data series of the impact of maintenance pemetrexed in 1st line NSCLC
Median OS of 18.6 mo vs 19.5 Mo (not significant) with or without maintenance pemetrexed in 1000 pt case series:
sciencedirect.com/science/ar…
Angelo Dipasquale retweeted
A letter to editor we received and our response to it, both published in the February edition of @TheLancetOncol. Please read both and decide for yourself.
Angelo Dipasquale retweeted
What if we’ve been overdosing immunotherapy all along?
In our Ph III DELII study, 20 mg nivolumab q2w beat chemo in OS, with less toxicity, better QoL. It's time to rethink ICI dosing-for science and equity! ascopubs.org/doi/10.1200/JCO… @JCO_ASCO @OncoAlert @TataMemorial @SuyogCancer
Angelo Dipasquale retweeted
Artificial intelligence agents in cancer research and oncology
- Truhn 2026, Nature Reviews Cancer
Angelo Dipasquale retweeted
Interpreting the results of noninferiority trials: a review
nature.com/articles/s41416-0… via @petersasieni et al
Angelo Dipasquale retweeted
Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer cancertreatmentreviews.com/a…
Angelo Dipasquale retweeted
A fascinating new analysis in @JAMANetworkOpen (Nov 2025) highlights a paradox many clinicians recognize but rarely discuss openly:
PARP inhibitors dramatically improve PFS… yet OS differences remain blurred. Why?
Because in nearly all major trials, crossover allows placebo patients to receive PARP at progression — narrowing survival curves and diluting OS signals.
Is this PFS gain meaningful?
For many patients: absolutely.
It means longer chemo-free intervals, fewer complications, and the psychological relief of delaying relapse.
The real question becomes:
How much is that extra “quality time” worth — especially given the 2.4× higher risk of Grade 3–4 toxicity?
#OvarianCancer #PARPInhibitors #Oncology #JAMA #GynecologicOncology #BRCA #CancerResearch #PrecisionMedicine
Angelo Dipasquale retweeted
🚀 KRAS: From “Undruggable” to the Hottest Target in Oncology 🔥🧬
KRAS is the most mutated oncogene in cancer - yet for decades it was “undruggable.”
2025 marks a turning point.
A brand-new Signal Transduction & Targeted Therapy review lays out the ENTIRE evolution:
• Why KRAS drives PDAC, CRC, NSCLC
• Why G12C inhibitors work but only partly
• Why resistance is inevitable
• What the next wave of KRAS therapies looks like
🔑 Key takeaways:
🧩 KRAS mutations = ~30% of all cancers
– PDAC: 80–90%
– CRC: ~40%
– NSCLC: ~20% (G12C dominant)
🧬 Approved “OFF-state” inhibitors:
•Sotorasib
•Adagrasib
➡️ ORR ~30–40%, PFS ~6 months.
➡️ Resistance? Guaranteed.
🔥 Major resistance mechanisms:
– Secondary KRAS mutations (Y96D/S, G13D, A59…)
– RTK pathway upregulation
– EMT & squamous transformation
– KRAS amplification
– KEAP1/STK11/TP53 co-mutation biology
💡 The future = multi-modal KRAS targeting:
– Pan-RAS inhibitors
– G12D inhibitors (MRTX1133-like)
– SOS1/SHP2 inhibitors combos
– KRAS degraders (PROTACs)
– KRAS vaccines & cell therapies
– RNA & antisense therapeutics
🧠 The review beautifully shows KRAS as a signaling “master switch” with MAPK, PI3K, Ral, RAC1, Hippo/YAP-TAZ crosstalk explaining why single-agent inhibition fails.
🎯 Bottom line:
KRAS is no longer undruggable - it’s just very hard to drug.
The next breakthroughs will come from combos + pan-KRAS + epigenetic modulation + TME targeting.
🔖 Save this - it’s THE 2025 roadmap for KRAS-targeted therapy.
📖 Full paper cited below.
#OncoTwitter #MedTwitter #LCSM #GIOnc #TargetedTherapy @myESMO @OncoAlert @ESMO_Open
